Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

References

• Slamon DJ. Proto-oncogenes and human cancers. N Engl J Med. 1987;317(15):955–957. doi:10.1056/NEJM198710083171509.
   PubMedGoogle Scholar
• Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi:10.1056/NEJMoa1413513.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756–2764. doi:10.1038/bjc.2014.174.
   PubMed Web of Science ®Google Scholar
• Spano J.P, Beuzeboc P, Coeffic D, Arnould L, Lortholary A, Andre F, Ferrero J-M. Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: results from the French cohort study LHORA. Breast. 2015;24(4):376–383. doi:10.1016/j.breast.2015.02.035.
   PubMed Web of Science ®Google Scholar
• Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JLB, et al. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy. PLoS One. 2014;9(10):e109611. doi:10.1371/journal.pone.0109611.
   PubMed Web of Science ®Google Scholar
• Extra J.M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla J-P, Spielmann M, Mauriac L, Misset J-L, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15(8):799–809. doi:10.1634/theoncologist.2009-0029.
   PubMed Web of Science ®Google Scholar
• van ‘T Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, Van Der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536. doi:10.1038/415530a.
   PubMed Web of Science ®Google Scholar
• Li L.F, Xu X.J, Zhao Y, Liu Z.B, Shen Z.Z, Jin W.R, Shao Z.M. Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat. 2009;113(2):231–237. doi:10.1007/s10549-008-9925-4.
   PubMed Web of Science ®Google Scholar
• Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A. 2013;110(16):6388–6393. doi:10.1073/pnas.1219651110.
   PubMed Web of Science ®Google Scholar
• Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;155(3):589–595. doi:10.1007/s10549-016-3705-3.
   PubMed Web of Science ®Google Scholar
• Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;159(2):367–374. doi:10.1007/s10549-016-3933-6.
   PubMed Web of Science ®Google Scholar
• Park SL, Fesinmeyer MD, Timofeeva M, Caberto CP, Kocarnik JM, Han Y, Love S-A, Young A, Dumitrescu L, Lin Y, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(1):djt319. doi:10.1093/jnci/dju061.
   PubMedGoogle Scholar
• Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205–212. doi:10.1038/modpathol.2009.159.
   PubMed Web of Science ®Google Scholar
• Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch. 2010;457(4):467–476. doi:10.1007/s00428-010-0964-y.
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, Buluwela L, Diez-Rodriguez M, Caldas C, Green AR, et al. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat. 2016;159(2):215–227. doi:10.1007/s10549-016-3934-5.
   PubMed Web of Science ®Google Scholar
• He, L., Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, et al. Targeting androgen receptor in treating HER2 positive breast cancer. Sci Rep. 2017;7(1):14584. doi:10.1038/s41598-017-14623-2.
   PubMedGoogle Scholar
• Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–689.
   PubMed Web of Science ®Google Scholar
• Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995;9(4):444–450. doi:10.1038/ng0495-444.
   PubMed Web of Science ®Google Scholar
• Pistelli M, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer. Ann Oncol. 2016;27(suppl 6). doi:10.1093/annonc/mdw141.
   Google Scholar
• Kim H, D’Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012;26(13):1393–1408. doi:10.1101/gad.195248.112.
   PubMed Web of Science ®Google Scholar
• Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, Collavoli A, Falaschi E, Rossetti E, Aretini P, et al. MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers. Eur J Med Genet. 2015;58(10):531–539. doi:10.1016/j.ejmg.2015.09.005.
   PubMed Web of Science ®Google Scholar
• Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7(5):R788–R795. doi:10.1186/bcr1304.
   PubMed Web of Science ®Google Scholar
• Andre F, Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015;150(1):1–8. doi:10.1007/s10549-015-3301-y.
   PubMed Web of Science ®Google Scholar
• Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun. 2011;407(1):219–224. doi:10.1016/j.bbrc.2011.03.002.
   PubMed Web of Science ®Google Scholar
• Paplomata E, O’Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154–166. doi:10.1177/1758834014530023.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol. 2016;27(10):1867–1873. doi:10.1093/annonc/mdw262.
   PubMed Web of Science ®Google Scholar
• Gagliato DM, Fontes Jardim DL, Pereira Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016. doi:10.18632/oncotarget.7043
   Google Scholar
• Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kücücük S, Dincer M, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 2008;19(4):669–674. doi:10.1093/annonc/mdm522.
   PubMed Web of Science ®Google Scholar